On a scorching summer day, the Lecheng Pilot Zone has recently experienced an explosive level of heat. On the afternoon of July 29th, the Japan International Investment Promotion Conference for the Boao Lecheng International Medical Tourism Pilot Zone in Hainan was held at the Never ending International Innovative Medicine and Equipment Exhibition in the Lecheng Pilot Zone. Representatives of over 80 well-known Japanese pharmaceutical enterprises, investment institutions, medical institutions, associations and associations, as well as more than 200 guests participated online and offline.
The focus of this Japan International Investment Promotion Conference is on Japanese medical institutions, pharmaceutical device manufacturers, and medical service institutions. The aim is to fully leverage the policy advantages of urgently needed imported medical devices and real-world research in the Lecheng Pilot Zone, continuously introduce high-quality medical and health resources, accelerate the use of foreign innovative medical devices in the Lecheng Pilot Zone, and promote their registration and listing in China, injecting new vitality into the high-quality development of the Lecheng Pilot Zone.
Jia Ning, Secretary of the Party Committee and Director of the Lecheng Pilot Zone Management Bureau, pointed out in his opening speech that under the combination of multiple policy advantages such as Hainan Free Trade Port and the "Two Countries and Nine Articles", the golden brand effect of Boao Lecheng has been continuously demonstrated, becoming a new paradise for the biopharmaceutical industry. High quality industrial resources such as domestic and foreign pharmaceutical and equipment enterprises, medical institutions, medical colleges, and CRO organizations have gathered, helping Lecheng move from a policy highland to an industrial innovation and development highland. He said, "This year is a crucial year for the construction of Hainan Free Trade Port and the high-quality development of Lecheng Pilot Zone. Here, we sincerely invite representatives of Japanese entrepreneurs present to visit Lecheng for inspection, exchange, and joint development. Lecheng Management Bureau will surely demonstrate the highest efficiency, the best policies, and the most practical measures to create the optimal business environment, so that the project can be implemented as soon as possible and the enterprise can benefit as soon as possible
Xu Lan, a member of the Party Group and Deputy Director of the Hainan Provincial Development and Reform Commission, mentioned that with the continuous promotion of free trade port construction and the continuous release of policy dividends, Hainan has continuously optimized its business environment, providing a good industrial development environment and greater development opportunities for pharmaceutical enterprises. As the business supervisory department of Lecheng Pilot Zone, the Provincial Development and Reform Commission will continue to strive to build Lecheng Pilot Zone into a gateway for international advanced medicine and equipment to enter China, allowing more innovative medicine and equipment to provide better protection for the lives and health of the people.
Zhang Yuhui, member of the Party Committee and Deputy Director of the Hainan Provincial Health Commission, introduced that the Lecheng Pilot Zone is the core of the development of Hainan's health industry. Led by institutional integration and innovation, the Provincial Health Commission has increased simplification of administration and decentralization, innovated regulatory models, accelerated the implementation of preferential policies, actively introduced high-quality medical resources from both domestic and foreign sources, and promoted the Lecheng Pilot Zone to basically achieve "three synchronization" of medical technology and equipment with international advanced levels.
Wang Gang, a member of the Party Leadership Group and Deputy Director of Hainan Drug Administration, said that in order to give full play to the Spillover effect of Lecheng's licensed medical equipment and real world research policies, the State Food and Drug Administration and the relevant technical departments of the Provincial Food and Drug Administration have established a smooth communication mechanism. Lecheng is a paradise for entrepreneurship and entrepreneurs. Japanese companies are welcome to visit and invest in Lecheng, and deeply participate in the construction and development of Lecheng.
Business Consul Abe Shangxing of the Consulate General of Japan in Guangzhou stated that the Lecheng Pilot Zone has developed into an international medical tourism service industry cluster mainly focused on licensed medical treatment, health management, and cosmetic medicine. We look forward to the Japanese companies present here, through today's investment promotion meeting, deepening our understanding of Lecheng Medical Pilot Zone, and seizing new business opportunities to jointly share the development opportunities and achievements of Hainan Free Trade Port.
Subsequently, Fu Zhu, a member of the Party Committee and Deputy Director of the Lecheng Pilot Zone Management Bureau, Bo Pei, a Senior International Affairs Officer of the Lecheng Pilot Zone Management Bureau, and Gao Jie, the head of the Investment Department of the Hainan International Economic Development Bureau, introduced a series of preferential policies around the Hainan Free Trade Port and Lecheng Pilot Zone
The Chairman and General Manager of Antai China and the General Manager of Antai Greater China Business District, Hamako Yang, the President of Eternal Lucky Group in China, Fan Yu, the Vice President of Sunrise Pharmaceutical (China) Co., Ltd., Naoyi Kamoto, and the Greater China Representative of Hesong Pharmaceutical Co., Ltd., Zhu Fangming, shared their investment and cooperation experience with Lecheng Pilot Zone.
Can you provide a detailed introduction to the specific process of introducing licensed medical devices? "" What types of medical device products are suitable for conducting real-world research in Lecheng The relevant leaders of Hainan Provincial Drug Administration, Lecheng Pilot District Management Bureau, Lecheng Pharmaceutical Regulatory Bureau and other units provided detailed answers one by one.
Fu Mingchao, chairman and chairman of the Hainan General Chamber of Commerce of Japan, said in an interview that Japan's medical industry is very developed, and Lecheng Pioneer Area is a window for China's reform and opening up in the medical field. He hoped that both sides would take this meeting as an opportunity to carry out more extensive and in-depth cooperation in the medical and health field. The Hainan General Chamber of Commerce of Japan will act as a bridge between Haolecheng and Japanese enterprises, and promote more medical institutions, medical technologies and pharmaceutical equipment to land in the city.The promotion meeting was guided by Hainan Development and Reform Commission, Hainan Health Commission, Hainan Drug Administration, hosted by Hainan Boao Lecheng International Medical Tourism Pilot Area Administration, co organized by Hainan International Economic Development Bureau and Hainan Overseas Chinese Affairs Office, and supported by Xianggang Weijian Pharmaceutical Group, TESCO Group, Mizuho Bank, and EPS International Holdings Co., Ltd.Fan Bin, Director of the Lecheng Medical Supervision Bureau, Fu Gan, Member of the Party Committee and Secretary of the Discipline Inspection Commission of the Lecheng Pilot District Management Bureau, Chen Wei, Deputy Director of the Overseas Chinese Affairs Management Division 2 of the United Front Work Department of the Hainan Provincial Party Committee, and Li Saimei, a Level 3 researcher of the Management Division 1; Daiichi Mitsubishi Co., Ltd., Takeda Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Ono Shopin Industrial Co., Ltd., Kissei Shopin Industrial Co., Ltd More than 60 pharmaceutical companies and medical institutions, including Mino Fayuan Pharmaceutical Co., Ltd. in Japan; More than 10 institutions and associations, including the Consulate General of Japan in Guangzhou, the Japan Chamber of Commerce in China, the Japan General Chamber of Commerce in Beijing, the Japan International Medical Policy Agency, the Japan International Education Agency Review Council, the Japan China Youth Economic and Cultural Exchange Association, the Japan Hainan General Chamber of Commerce, and other general corporate bodies; Eight investment companies, including Haozhou Aisprui Business Consulting Co., Ltd., Ruimin Bank, and Dapeng Pharmaceutical Information Consulting (Beijing) Co., Ltd., attended the meeting.